South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
The BioIndustry Association (BIA) has published new data revealing that the UK’s life sciences sector attracted £1.23 billion ($1.66 billion) in venture capital (VC) investment in the first half of 2025, thereby putting it on track to match or surpass 2024’s total. 28 July 2025
TCG Labs Soleil has secured another $400 million to expand its global R&D footprint and help build out its growing portfolio of single-asset biotechnology companies. The San Francisco-based venture firm said the new fund matches the size of its inaugural raise last year. 25 July 2025
It has been a stellar week for Abivax, a French biotech developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. 25 July 2025
The Trump administration has asked the US Supreme Court to allow the National Institutes of Health (NIH) to resume canceling hundreds of research grants supporting work on health equity, racial disparities, and other diversity-related public health initiatives. 25 July 2025
Australian venture capital firm Brandon Capital has closed its largest fund to date, raising A$439 million ($296 million) for its sixth life sciences fund. The final close brings in new government support, signaling increasing national focus on growing the domestic biotech sector. 24 July 2025
Dispatch Bio has announced its official launch, with the stated ambition of engineering a universal treatment across solid tumors, which represent approximately 90% of cancers worldwide. 23 July 2025
Switzerland-based Pharvaris yesterday announced the pricing of an underwritten offering of: 8,250,000 of its ordinary shares at a price of $20.00 per share and to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant. 23 July 2025
Cambridge, USA-based biotech Avalyn Pharma, which developing inhaled therapies for the treatment of life-threatening pulmonary diseases, has announced the closing of an oversubscribed $100 million Series D financing. 23 July 2025
French biotech One Biosciences has raised 15 million euros ($16 million) in series A financing to advance development of its clinical-grade single-cell tumor profiling technology. 17 July 2025
South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
California-based Renasant Bio announced its launch to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. 13 July 2025
Nuclidium, a radiopharma company developing a proprietary copper-based theranostic platform, has announced the successful closing of its Series B financing round, raising 79 million Swiss francs ($99 million). 11 July 2025
Chinese cell therapy developer NK CellTech has raised nearly 100 million renminbi ($14 million) in an extended series A+++ round to support the clinical development of its flagship NK cell therapies and broaden its pipeline. 11 July 2025
French biotech Ciloa is joining the race to treat type 2 diabetes and obesity, armed with 6.5 million euros ($7.6 million) in public funding and a novel take on an old metabolic target. 9 July 2025
San Francisco, USA-based biotech Centivax, which is developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors. 8 July 2025
US-Japan venture capital firm AN Venture Partners has wrapped up its first fund at $200 million, marking one of the largest biotech funds focused on Japan to date. The new vehicle, called AN Venture Partners I, is backed by over 20 limited partners, including Japanese drugmakers Shionogi and Otsuka Pharmaceutical. 3 July 2025
US biopharma Syntis Bio, which is developing oral therapies for obesity, diabetes and rare diseases, has announced the close of a $33 million oversubscribed Series A financing. 2 July 2025
PureTech Heath founded clinical-stage biotech Vor Bio has entered into an exclusive license agreement with RemeGen to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). 26 June 2025
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Geron Corporation, a biopharma company focused on telomerase inhibition therapies, has announced a $375 million financing agreement aimed at supporting the commercial rollout of Rytelo (imetelstat). 11 November 2024
US biotech venture fund Aditum Bio and China’s Leads Biolabs today announced the formation of Oblenio Bio, marking the thirteenth company launched by Aditum. 7 November 2024
PrognomiQ has announced a series D financing round of $34 million, led by Seer, bringing the firm’s total funding to over $135 million since its founding in September 2020. 6 November 2024
A new Seattle-based biotech company has the best endorsement imaginable as it emerges from stealth. Archon Biosciences’ platform, leveraging AI-driven advances in computational protein design, were recognized earlier this month by the awarding of the 2024 Nobel Prize in Chemistry, for its ability to create novel proteins with desired functions. 31 October 2024
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Oxford, UK-based Blue Earth Therapeutics, an emerging leader in the development of therapeutic radiopharmaceuticals, today announces completion of a $76.5 million Series A financing. 30 October 2024
San Francisco, USA-based biotech start-up Kivu Bioscience has announced the closing of a $92 million Series A financing round led by Novo Holdings, which as of year-end 2011123 had total assets of 149 billion euros ($161 billion). 28 October 2024
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Belgian biotech Agomab Therapeutics today announced a $89 million (82.1 million euros) Series D financing round, with participation from new investors Sanofi and Invus 25 October 2024
Alpha-9 Oncology, a Canadian radiopharmaceutical company, has raised $175 million in an oversubscribed series C financing round led by Lightspeed Venture Partners and Ascenta Capital. 24 October 2024
US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was led by global life sciences investor Novo Holdings. 23 October 2024
Boston, USA-based Seaport Therapeutics has announced the closing of an oversubscribed $225 million Series B financing round, adding to the $100 million it pulled in along with its launch in April. 21 October 2024
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
LaNova Medicines, a Shanghai-based biopharma company, has announced that it has secured 3 billion yuan ($41 million) in its series C funding round. 18 October 2024
California, USA-based biotech Terray Therapeutics, yesterday announced the closing of an oversubscribed Series B funding of $120 million. 18 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024